Immutep Hits 50% Enrolment Milestone in Global Phase III Lung Cancer Trial

An announcement from Immutep Ltd ( (AU:IMM) ) is now available.

Immutep has reached 50% patient enrolment in its global registrational Phase III TACTI-004 (KEYNOTE-F91) trial, with 378 patients now enrolled to evaluate its lead immunotherapy eftilagimod alfa in combination with Merck’s KEYTRUDA and chemotherapy as a first-line treatment for advanced or metastatic non-small cell lung cancer. The study, which targets approximately 756 patients across more than 25 countries, is progressing on schedule, with a futility analysis planned for the first quarter and full enrolment expected by the third quarter of 2026, underscoring the rapid recruitment pace and reinforcing Immutep’s bid to establish the combination as a potential new standard of care in one of oncology’s largest and most lethal indications.

The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.

More about Immutep Ltd

Immutep Limited is a late-stage biotechnology company specialising in novel immunotherapies for cancer and autoimmune diseases. A pioneer in LAG-3 (Lymphocyte Activation Gene-3) biology, the company develops treatments that modulate the immune system, with its lead asset eftilagimod alfa (efti) being tested across multiple solid tumours including non-small cell lung cancer, head and neck cancer, soft tissue sarcoma and breast cancer. Efti’s favourable safety profile supports combinations with anti-PD-[L]1 therapies, radiotherapy and chemotherapy, and it has secured Fast Track designation from the U.S. FDA in first-line NSCLC and head and neck cancer.

Average Trading Volume: 3,857,893

Technical Sentiment Signal: Buy

Current Market Cap: A$567.4M

See more data about IMM stock on TipRanks’ Stock Analysis page.